Cite
HARVARD Citation
Boye, K. et al. (2019). Generalizability of glucagon‐like peptide‐1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States. Diabetes, obesity & metabolism. 21 (6), pp. 1299-1304. [Online].